Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease
- PMID: 3998751
- PMCID: PMC1028327
- DOI: 10.1136/jnnp.48.5.413
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease
Abstract
Dementia in Parkinson's disease has previously been attributed to the presence in the cerebral cortex of Alzheimer-type neuropathological abnormalities. New evidence suggests, however, that dementia in this disease usually occurs in the absence of substantial Alzheimer-type changes in the cortex and may be related to abnormalities in the cortical cholinergic system. Thus, in Parkinsonian patients with dementia there were extensive reductions of choline acetyltransferase and less extensive reductions of acetylcholinesterase in all four cortical lobes. Choline acetyltransferase reductions in temporal neocortex correlated with the degree of mental impairment assessed by a test of memory and information but not with the extent of plaque or tangle formation. In Parkinson's but not Alzheimer's disease the decrease in neocortical (particularly temporal) choline acetyltransferase correlated with the number of neurons in the nucleus of Meynert suggesting that primary degeneration of these cholinergic neurons may be related, directly or indirectly, to declining cognitive function in Parkinson's disease.
Similar articles
-
Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases.J Neurol Sci. 1983 May;59(2):277-89. doi: 10.1016/0022-510x(83)90045-x. J Neurol Sci. 1983. PMID: 6854353
-
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.Br Med J. 1978 Nov 25;2(6150):1457-9. doi: 10.1136/bmj.2.6150.1457. Br Med J. 1978. PMID: 719462 Free PMC article.
-
[Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].Rev Neurol (Paris). 1985;141(3):184-93. Rev Neurol (Paris). 1985. PMID: 4001706 French.
-
The current status of the cortical cholinergic system in Alzheimer's disease and Parkinson's disease.Prog Brain Res. 1986;70:105-32. doi: 10.1016/s0079-6123(08)64300-9. Prog Brain Res. 1986. PMID: 3554348 Review. No abstract available.
-
Molecular forms of acetylcholinesterases in Alzheimer's disease.Fed Proc. 1986 Dec;45(13):2982-8. Fed Proc. 1986. PMID: 2430839 Review.
Cited by
-
Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction.J Parkinsons Dis. 2016 May 5;6(2):441-51. doi: 10.3233/JPD-150753. J Parkinsons Dis. 2016. PMID: 27164041 Free PMC article.
-
Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques.Acta Neuropathol. 1989;78(6):572-84. doi: 10.1007/BF00691284. Acta Neuropathol. 1989. PMID: 2683563
-
Cognitive-enhancing effect of quercetin in a rat model of Parkinson's disease induced by 6-hydroxydopamine.Evid Based Complement Alternat Med. 2012;2012:823206. doi: 10.1155/2012/823206. Epub 2011 Jul 18. Evid Based Complement Alternat Med. 2012. PMID: 21792372 Free PMC article.
-
Mild Cognitive Impairment in Parkinson's Disease-What Is It?Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):17. doi: 10.1007/s11910-018-0823-9. Curr Neurol Neurosci Rep. 2018. PMID: 29525906 Free PMC article. Review.
-
Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia.J Neurol Neurosurg Psychiatry. 1998 May;64(5):653-6. doi: 10.1136/jnnp.64.5.653. J Neurol Neurosurg Psychiatry. 1998. PMID: 9598683 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical